Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 67.1% during the fourth quarter, HoldingsChannel reports. The firm owned 24,674 shares of the biopharmaceutical company’s stock after purchasing an additional 9,908 shares during the period. Regeneron Pharmaceuticals comprises 1.6% of China Universal Asset Management Co. Ltd.’s holdings, making the stock its 12th biggest position. China Universal Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $17,576,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Adirondack Trust Co. lifted its position in Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the last quarter. Trust Co. of Vermont boosted its position in shares of Regeneron Pharmaceuticals by 8.3% during the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 12 shares during the period. Nvwm LLC increased its holdings in Regeneron Pharmaceuticals by 1.4% in the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its position in Regeneron Pharmaceuticals by 3.6% in the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on REGN shares. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $672.98 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company has a 50-day simple moving average of $720.81 and a 200-day simple moving average of $924.07. The stock has a market capitalization of $73.95 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.